In 2019, the US Food Drug Administration (FDA) issued warning letters to 19 Indian pharma giants. The number has drastically increased from 10 companies in 2018. The USFDA issues warning letters to pharma companies if the products do not meet specific regulatory requirements. The warning letter makes clear that the company must correct the problem and plan in a timeframe to inform FDA for its correction, according to USFDA.
Some of the key reasons for receiving warning letters include data integrity, insufficient documentation, misleading claims about the efficacy and risks associated with the use of a drug product, significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and Active Pharmaceutical Ingredient (APIs), commercialization of unapproved or misbranded drugs.
Indian companies are at paramount of receiving warning letters owing to the rise in an inspection by the USFDA. Sharing his views on this Sudarshan Jain, Secretary-General, Indian Pharmaceutical Alliance (IPA), Mumbai says “There is an increase in FDA inspections in India from earlier 13 percent in 2018 to 17 percent YTD 2019 of global inspections this year. This is obvious given India’s contribution to the US healthcare system as every third tablet sold in the US is from India.” The USFDA which has established its office in India in 2008 has increased its inspections. In 2017, USFDA has 147 inspections which have gone up to 192 in 2018. In 2016 the number inspections done by USFDA were 176.
“India is crucial for the US market as India has got the highest number of FDA approved manufacturing facilities. Hence, vigilance on India would always be high and any issues related to quality in the US due to Indian players will bring FDA vigilance under criticism as well”, says Prashant Khadayate – Practice Head, Healthcare, GlobalData.
Denne historien er fra February 2020-utgaven av Bio Spectrum.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra February 2020-utgaven av Bio Spectrum.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Economic Survey Lays Focus On Mental Healthcare For The First Time
For the first time ever, the Economic Survey 2023-24 tabled by the Union Minister of Finance and Corporate Affairs Nirmala Sitharaman in Parliament recently, talks extensively about mental health, its significance and implications on policy recommendations.
IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus
Indian Institute of Technology Guwahati (IIT-G) researchers have investigated the biochemistry of the African Swine Fever Virus (ASFV) protein, focusing on understanding the biochemical processes of infection to devise effective control strategies.
13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors
The 13th edition of Bengaluru INDIA NANO 2024, organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS), and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) concluded on August 3 with participation of 1018 delegates, 11 countries including Korea, Morocco, USA, UK, France, Canada, Germany, Netherlands, Russia, Japan, and Poland, 49 exhibitors comprising 21 startups and 28 industry and institutes, and 200 posters. The exhibition had a footfall of 3,000+ visitors.
Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle
The news has been around for a while which has put a big question mark ahead of the Indian nutraceuticals industry.
Can India Reclaim API Throne from China?
Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).
JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana
JRS Pharma, a leading manufacturer of excipients, in partnership with Gujarat Microwax, has commissioned a new manufacturing facility for cotton-based croscarmellose sodium.
NovaLead's patented repurposed drug for treating DFU gets CDSCO approval
Pune-based NovaLead Pharma has announced that the drug regulator in India, Central Drugs Standard Control Organisation (CDSCO), has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need.
Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda
Delhi-based pharma company Medicamen Organics has taken a significant step in its global expansion strategy by signing a Memorandum of Understanding (MoU) with Depot Pharmacy Yego in Rwanda.
Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr
Mankind Pharma has entered into a definitive agreement to acquire a 100 per cent stake in Bharat Serums and Vaccines Limited (BSV) from Advent International, for an enterprise value of approx.
Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence
Mumbai-based Thyrocare, a leading diagnostic and preventive healthcare service provider in India, has entered into a Business Transfer Agreement with Polo Labs to acquire their pathology diagnostic business.